ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2020
The AT(N) framework for Alzheimer's disease in adults with Down syndrome.
Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Inflammation Associated With Obesity, Aging, and Amyloid Burden in Adults With Down Syndrome.Obesity (Silver Spring, Md.) · 2026Article
- Imaging and plasma biomarkers for pathological accumulation in Down syndrome.Brain : a journal of neurology · 2026Article
- Precision medicine for Alzheimer's disease in Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Development of Molecular Neuropathology in Down Syndrome across the Lifespan.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025Review
- Alzheimer's Disease Research Center Down Syndrome Cores: Experience from two sites.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Staging of Alzheimer's disease progression in Down syndrome using mixed clinical and plasma biomarker measures with machine learning.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Joint spatial associations of amyloid beta and tau pathology in Down syndrome and preclinical Alzheimer's disease: Cross-sectional associations with early cognitive impairments.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- The Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) and its contributions to understanding Alzheimer's disease in Down syndrome: A decade of discovery.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Longitudinal study of body mass index in relation to Alzheimer's disease pathology and symptomatology in Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- The Alzheimer's Biomarker Consortium-Down Syndrome (ABC-DS): A 10-year report.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Blood biomarkers in Down syndrome: Facilitating Alzheimer's disease detection and monitoring.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Assessing amyloid PET positivity and cognitive function in Down syndrome to guide clinical trials targeting amyloid.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Cerebrovascular disease emerges with age and Alzheimer's disease in adults with Down syndrome.Scientific reports · 2024Article
- Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study.The Lancet. Neurology · 2024Observational
- The Single Toxin Origin of Alzheimer's Disease and Other Neurodegenerative Disorders Enables Targeted Approach to Treatment and Prevention.International journal of molecular sciences · 2024Review
- AT(N) biomarker profiles and Alzheimer's disease symptomology in Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- A pathway linking pulse pressure to dementia in adults with Down syndrome.Brain communications · 2024Article
- Pathways linking pulse pressure to dementia in adults with Down syndrome.medRxiv : the preprint server for health sciences · 2023Article
- The Global Deterioration Scale for Down Syndrome Population (GDS-DS): A Rating Scale to Assess the Progression of Alzheimer's Disease.International journal of environmental research and public health · 2023Article
- Association of biological sex with clinical outcomes and biomarkers of Alzheimer's disease in adults with Down syndrome.Brain communications · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
The National Institute on Aging in conjunction with the Alzheimer's Association (NIA-AA) recently proposed a biological framework for defining the Alzheimer's disease (AD) continuum. This new framework is based upon the key AD biomarkers (amyloid, tau, neurodegeneration, AT[N]) instead of clinical symptoms and represents the latest understanding that the pathological processes underlying AD begin decades before the manifestation of symptoms. By using these same biomarkers, individuals with Down syndrome (DS), who are genetically predisposed to developing AD, can also be placed more precisely along the AD continuum. The A/T(N) framework is therefore thought to provide an objective manner by which to select and enrich samples for clinical trials. This new framework is highly flexible and allows the addition of newly confirmed AD biomarkers into the existing AT(N) groups. As biomarkers for other pathological processes are validated, they can also be added to the AT(N) classification scheme, which will allow for better characterization and staging of AD in DS. These biological classifications can then be merged with clinical staging for an examination of factors that impact the biological and clinical progression of the disease. Here, we leverage previously published guidelines for the AT(N) framework to generate such a plan for AD among adults with DS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.